News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pozen, Inc. (POZN) Submits Final Study Report For PA8140/PA32540 Phase 1 Study On Schedule


4/2/2014 8:32:57 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that they have submitted the final study report for the Phase 1 study comparing the pharmacokinetic profile of the omeprazole component of PA8140 tablets to that of PA32540 tablets as agreed with the U.S. Food and Drug Administration.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES